WebMay 25, 2024 · 1036 Background: Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable linker, and a cytotoxic topoisomerase I inhibitor. In the pivotal DESTINY-Breast01 trial, efficacy of T-DXd in HER2-positive metastatic breast cancer (mBC) was demonstrated, with an objective … WebAug 17, 2024 · Transcript: Komal Jhaveri, MD, FACP: Let me just quickly walk us through the DESTINY-[Breast]03 trial [NCT03529110]; this was the very first randomized study of trastuzumab deruxtecan [T-DXd ...
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast …
WebApr 11, 2024 · Breast Screening Recommendations for Women at Higher-Than-Average BC Risk. Regardless of individualized BC risk, breast screening has proven to be a major contributor to detecting early stages of BC and improving survival outcomes. However, in women at increased risk, the fraction of false-negative findings becomes higher. WebApr 12, 2024 · Pancreatic ductal adenocarcinoma (PDAC), an aggressive and lethal cancer with 5-year overall survival of 10%, is the seventh leading cause of cancer death worldwide [1, 2].Most patients are diagnosed in the advanced stage too late for curable operation; thus, systemic therapy is essential [].As living drugs, chimeric antigen receptor (CAR-T) … crystal vision eyewear
Year in Review: HER2-Positive Breast Cancer MedPage Today
WebDec 7, 2024 · Updated results from the DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer … WebDec 10, 2024 · The median progression-free survival (PFS) was 19.4 months. In an exploratory landmark analysis of overall survival (OS), … WebOct 21, 2024 · At the most recent data cutoff, the median duration of overall survival follow-up was 29.2 months, and the updated median overall survival was 28.4 months; there were 91 overall survival events. The estimated overall survival rate at 18 months was 75%, … A nonprofit African American breast cancer survivors’ organization, it promotes the … Breast Cancer New! Hepatobiliary Cancers Immunotherapy Multiple Myeloma Non … dynamic planner spotlight report